Plain-English translation of NCT06792253 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called Ifupinostat Hydrochloride combined with rituximab (a well-established cancer drug) in people whose diffuse large B-cell lymphoma has either returned after treatment or stopped responding to it. The researchers want to see if this new combination works better than the standard chemotherapy options currently used for this situation. About 416 people will participate, with half receiving the new treatment and half receiving standard care.
Diffuse large B-cell lymphoma that comes back or stops responding to initial treatment is very serious, and current standard chemotherapy options have limited success. This trial exists to see whether this new medication, when combined with rituximab, can offer patients a more effective option.
You likely qualify if…
You likely don't qualify if…
If you join, you'll first go through a screening period (up to 3 weeks) with imaging scans and blood tests. Then you'll receive treatment in 3-week cycles for 8 cycles total—either the new medication combination or standard chemotherapy, depending on which group you're randomly assigned to. The new medication is given as injections on specific days of each cycle. You'll have imaging scans every 6 weeks during the first 8 cycles to check how the cancer is responding. If the new treatment works well for you, you may continue with maintenance treatment for up to 2 years. After treatment ends, you'll have follow-up visits to monitor your health and check for cancer recurrence.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China